Johnson & Johnson's Single-Dose COVID-19 Vaccine Approved For Use In 27-Nation European Union
Johnson & Johnson's Single-Dose COVID-19 Vaccine Approved For Use In European UnionEuropean Union flag. (Flickr/Bankenverband - Bundesve)

The European Union (EU) has approved the use of the single-dose COVID-19 vaccine developed by the United States (US) based pharmaceutical major Johnson & Johnson (J&J), reports Economic Times.

This makes J&J's vaccine the fourth jab to have been approved for administration in the 27 nations which are part of the EU. The other approved vaccines include those developed by Pfizer-BioNTech, Moderna and AstraZeneca-Oxford.

The latest approval to J&J vaccine is likely to give a boost to the block's vaccination programme, even though the first shipments of J&J doses may not arrive in European countries until April.

European Medicines Agency (EMA), the EU drug regulator, noted that the clinical trials involving volunteers in the United States, South Africa and South American countries found the Johnson & Johnson vaccine was 67 per cent effective at preventing people from getting COVID-19.

EMA also observed that the side effects were observed to be "usually mild or moderate" which cleared within a couple of days, including pain at the injection site, headache, tiredness, muscle pain and nausea.

An Appeal...

Dear Reader,

As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.

Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.

We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.

Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.

Become A Patron
Become A Subscriber